Skip to main content

Labcorp Holdings Inc Investor Event Transcript, Nov 10, 2026

Labcorp Holdings Inc. (LH)

LabCorp reported third-quarter revenue growth of 7%, margin expansion of 60 basis points and adjusted EPS growth of 14.5%, raising full-year revenue guidance by $65 million and adjusted EPS guidance by 18 cents. AI summary

Investor Event Transcript 2026-11-10 For: 2026-12-31
Added on November 11, 2026

Conference Transcript - LH 2026-11-10

Kevin Caliendo, Analyst — UBS

All right. Good morning, everybody. Welcome to day two of the UBS Global Healthcare Conference. I'm Kevin Caliendo, Healthcare IT Distribution Analyst here at UBS, and we are very proud and happy to have with us Management from LabCorp, Julia Wang, who is the Chief Financial Officer. Julia, thank you so much for coming down.

Julia Wang, CFO

Hi, Kevin. So happy to be here, and thank you for having us.

Kevin Caliendo, Analyst — UBS

By the way, people on the table, there's a QR code. If you want to send in a question, feel free to do so. I have an iPad up here, and the question's not illicit. I'm happy to ask it. So let's talk a little bit about 2Q. It was a really good print. It was one of the best prints you've had, really, in years. Organic growth, 5.5%, which was up sequentially, even though all of the utilization trackers weren't necessarily better, which maybe suggests you took share. There was also the sixth straight quarter of margin progression. If you look back at the third quarter, what was maybe the one thing that surprised you to the upside or was better than maybe what you had thought?

Julia Wang, CFO

Yeah, that's right. So we delivered strong performance in the third quarter, for sure, whereby we grew revenue by 7%, expanded margin by 60 basis points, and grew adjusted EPS by 14.5%. Based on that strength and momentum, we actually raised the midpoint of our guidance ranges for revenue by $65 million and for adjusted EPS by 18 cents. If I were to point out one area that has delighted me to the upside, I would have to say hands down to the continued strength in our central lab service business. As you know already, in the third quarter, we grew revenue in central lab service at an organic constant currency basis of 11.3%. Thank you. And that growth was primarily driven by underlying demand and also benefiting a bit from accelerated study stars. So we are definitely pleased with the trajectory of Central Lab. Now, if I step back, look at the quarter and even beyond the quarter, what we find encouraging is that we deliver the strong growth, we expanded the margins, we raised guidance, and then we have momentum. So it's really the combination of all those positive indicators that reinforce. For us in terms of our confidence about the durability of our growth algorithm as we head into 2027.

Kevin Caliendo, Analyst — UBS

That's great. The central lab number was really, really impressive. I think it was constant currency growth was 11.3 versus what you had seven and a half prior. What are, when you say study starts, is this new trial starts that you were just, was it you taking share there or just happened your customers were in particular? Did the market accelerate this way? Was it, I guess what I'm asking is, is this LabCorp specific? Was it market specific? Is it? And how durable is it, really? Because, I mean, your guidance now, I believe, is high single digits, which is better than 2Q, but not quite as good as 3Q.

Julia Wang, CFO

That's right. Yeah. So if I look at the central net business, as you were saying, in the third quarter, once again, the revenue growth at an organic constant currency basis was 11.3 percent. And the key driver behind that growth was underlying demand. The study starts was a little bit kind of based on the pacing of the customer that was put forward a bit, although that was the tailwind, but not the primary driver for sure. And then to your point, if you look at over a little bit longer period of time, Q3 year to date, sales, escrow, revenue, cost and currency, organic basis, about 8%. And then at the end of Q3, we actually raised the full-year guidance for the central lab businesses to expect a high single-digit revenue growth on organic cost and currency basis for 2026. I think equally encouraging is if you look at another indicator of the health of the business, it's really the book-to-bill ratio. We delivered a 1.13 in the quarter, which translates into a 1.10 for training 12 months. Now, we do not break out the specific book-to-build for Central Lab and ED within our BLS segment. However, what I can reinforce is that the Central Lab business continues to be strong from a book-to-build perspective, and then ED booking has continuously been improving. So, once again, the area that gives us continued optimism about that business is where I look at our customer group, the growth both in revenue as well as in booking is very broadly based, and it's also very aligned with our specialty testing focus as a company, which we can talk a little bit more during this conversation here. Thank you. You know, at the end of the day, I would just say that all the indicators are giving us confidence about the continued strength and momentum in Central Lab as we have to execute against the outlook for the next three years.

Kevin Caliendo, Analyst — UBS

Can we talk about the diagnostic business a little bit?

Julia Wang, CFO

Let's do that.

Kevin Caliendo, Analyst — UBS

So in the quarter, organic volumes accelerated, which everybody loved to see, right? It went to 3.1% quarter over quarter versus 1.8%. So price mix slowed a little bit. And I know we asked you this on the call, I believe. Was there anything in particular about the mix that maybe prompted volumes to accelerate and price growth to decelerate a little bit versus what they had been? Adam said, don't read into any one quarter. But was there anything there? And how should we think about those two variables going forward, volume versus? Pricing.

Julia Wang, CFO

Yeah, that's no, Denise. So, From a diagnostic perspective, we also delivered strong performance in the third quarter. As you were saying, if you just look at the organic revenue growth, we delivered 4.4%, and that included a volume contribution of 3.1% and a price mix contribution of 1.3%. And, of course, in line with what Adam has shared in the past, when you look at the contribution of volume growth visibly a price mix variability to organic revenue growth, you would want to give it a little bit of time perspective versus just one single quarter because for a complex business like ours, you inevitably could be having some variability from quarter to quarter, right? So if you step back and start from the organic volume growth, I would say for the first three quarters, we grew about 2%. And then that strength, of course, is really at the high end of the market, right? Just from an organic perspective, if you put in acquisitions, obviously outpacing the market growth as we've laid out in our strategy. And then from a price mix perspective, we continue to see benefit of the increase in test-apart accession as we have been consistent in our communication. So the test-apart accession has been a consistent contributor to the revenue growth from an organic perspective for sure. And if you expand a little bit there, you just look at the contribution of esoteric revenue to the total diagnostic revenue over time. It has actually been growing much faster than the routine testing. Back in the first part of 2024, esoteric testing accounted for 38% of total diagnostic revenue, and that ratio has improved to about 42% in Q3 of this year. So when you think about the key drivers behind that growth, it's absolutely in line with our strategy around the leading specialty testing, because what we have found is that when you win in specialty testing, you tend to win in the broader testing of a patient's need, particularly when you consider our overall value proposition, right? Because we are a very comprehensive testing provider that has a menu as extensive as 6,500 tests, and we perform 750 million tests every single year to be able to serve the patients. So to have that focusing specialty and then not only growing specialty, but also grow through this pull-through, if you will, is a very conducive place to be. And for the full year, actually, we have reached the midpoint of our revenue guidance for diagnostics. We're expecting 5.9% of revenue growth at the midpoint, and the expectation continues to be for organic performance to be the key driver for the total revenue growth. And within the organic, we expect the volume growth to be slightly outpacing the fearability in price mix. So as we head into 2027 and beyond, you know, we continue to expect to really drive above market growth through leveraging strong underlying demand in the marketplace. Our own strategic focus, particularly through the partnerships, as well as the specialty testing, and then being able to benefit from price mix availability to drive margin expansion.

Kevin Caliendo, Analyst — UBS

Super helpful and very consistent messaging, which we all appreciate. Where can esoteric testing go, 38 to 42 in a year and a half, in essence? Is it eventually the goal of the company? Can it be 50% of your volumes can be esoteric, or is that asking too much? What's the ceiling or what's the pathway? How do you think about it? And actually, maybe the second question, because this confuses people sometimes. What's the margin difference? Gross margin, operating margin, difference, esoteric versus routine.

Julia Wang, CFO

Yeah, yeah, so there are two parts. Yeah, two parts. That's one question. Go through one at a time. If I could start from the question as it relates to the esoteric testing trend and all of that, while we have not necessarily put a specific mixed target out there, but what we did do is really share the momentum at our recent investor day in September in New York City. You might recall that we actually sized this book of the business to be about $2 billion in sales on an absolute basis at this moment in time. And when you look at the past three years between 2022 to 2025, from a CAGR perspective, the growth within the specialty area, and by the way, we have four areas, which you may know already, right? We have oncology, neurology, women's health, and autoimmune, right? So those four areas make up the specialty focus. And if you look at the category between 2022 to 2025, it's really a growth rate of 10% for women's health to 15% for oncology, as well as autoimmune, and then 25% for neurology, right? So clearly, it's very strong growth. While acquisitions have contributed, but even if you were to exclude the acquisitions, the underlying call operational growth still were very strong. And then, you know, going forward, you know, I would say our focus is really, really relentless because the way we think about specialty testing is, once again, we are very agnostic in terms of how we access new innovation and new testing solutions. Whether it's we get access through internal R&D efforts or we could always partner in various ways, shape, and form, right? It could be an acquisition. It could be a licensing. We have multiple examples like that. We did the acquisition of Invita a few years ago, which we have very successfully integrated. We just recently announced a deal about Myriad Genetics, where we're super excited about the test that they newly launched, which is the first gene prenatal women's health testing, which we can talk a little bit more. We are very open to how we access testing. So all in all, at the end of the day, we wanted to ensure that we leverage our extremely extensive operating infrastructure, commercial infrastructure, broad-based portfolio, and kind of a one place of a comprehensive testing provider that removes friction from the healthcare system. Because when a doctor is trying to prescribe, they don't have to think twice to say, oh, this is specialty I have to send to one service provider, or this routine I have to send to a different one. They can just work with one company all the way from placing the order, performing the test, reporting all the results, and then digesting and dissecting, understanding, you know, kind of the whole diagnosis and being able to lead to the treatment pathway. So we're definitely excited about the specialty testing growth potential. And then the second part to the question is about margin. So it is interesting from a margin standpoint, but, you know, earlier I talked about it's been a very important enterprise focus for us as a company, and we've delivered six quarters consecutively already from a margin expansion perspective and supported by both operating segments. And then if we were just to zoom in the margin profile for diagnostics, right, the way we think about it internally is really, you know, the most profitable test is actually the incremental test we could drive through a single session, right? Essentially, if a session on the margin has more number of tests than historically speaking, then what we are able to do is really leverage a relatively fixed cost-oriented infrastructure, because in that case, we've already paid for the cost associated with collection of the sample, with transportation of that sample from the collection site to our testing facilities, right? And then we're able to quickly plug that into our testing infrastructure, and then, of course, our reporting infrastructure, and then the collection efforts through revenue cycle management. So this whole dynamic as it relates to the number of tests per session improvement, quarter in, quarter out, is no doubt a meaningful contributor to margin expansion, historically speaking, but definitely we expect that contribution going forward.

Kevin Caliendo, Analyst — UBS

This test per session has been trending up, whether it's because of GLP-1s or just more wellness testing or the like. The question is, how durable is that? Meaning, did we have a step function up in 2026, and now we're at a new level? Or do you anticipate, or is there a pathway that test per session can continue to grow? And how much of that is macro, and how much of that is? LabCorp.

Julia Wang, CFO

Yeah. Yeah, yeah, definitely. So the test processions you were saying, we've been seeing that benefit for quite some time now. And quite honestly, initially started from the moment that we got out of COVID. We actually saw a meaningful uptake in test procession following COVID. And of course, at that time, it was really attributed to kind of a pent up demand catching up, right? People were getting out of COVID. They were really catching up on testing needs and all that. Since that time, though, I would say every single quarter, you would be able to see a slight yet consistent increasing number of tests per session. And even though the improvement is relatively speaking small, but because we have this vast portfolio of 750 million tests every year, that's why when you translate that to a revenue contribution, it's actually meaningful. Now, to go back to your question about the durability of that, we actually believe the underlying drivers for this dynamic is structural in nature, right? It's also a combination of both utilization environment from a market perspective, as well as our specific and intentional strategy and execution. So let me break it down first. So, from a market standpoint, we've all been seeing this factors in healthcare overall, whether it's the aging population, which inevitably would need to more testing and healthcare need over a lifespan. Of course, there are dynamics as it relates to the prevalence of disease. You know, the heightened focus on just the wellness from a consumerism perspective. But then if you think about innovation, diagnostic innovation, right, today I would say the types of testing that is available to the broader testing populations is much more meaningful than it was 10 years ago or five years ago, right? So when you have more testing options for the patient, that, you know, everything else being equal, you know, provides an opportunity for growth. But when I think about our own strategy and execution, we talked at length about, you know, the partnership along with the health systems and the hospitals and our maniacal focus on specialty and also through elevating specialty in order to really ultimately elevating broader testing growth. So all of that, I would say, actually come together, support this expectation of number of tests per session to continue to be a tailwind for years to come.

Kevin Caliendo, Analyst — UBS

So maybe if I can narrow that down, when we think about your LRP that you put out the analyst day, how should we think about? Test per session, traditional organic volume growth, and pricing going into the sort of diagnostic top line. I know you have M&A in there, too, but I'm just talking about the organization.

Julia Wang, CFO

Yeah, so let's start with the outlook, right? As you were saying, our investor day in September, we established the long-term outlook for the next three years, spanning 2027 to 2029. And from a diagnostic perspective, we are looking for organic revenue growth of three and a half to five and a half. And then the... Sorry, is that Total Company? For the company, diagnosis 2.5 to 4.5. Okay, so let me reiterate. So total company organic growth, 3.5 to 4.5, and then diagnostic segment in particular, 2.5 to 4.5, organically speaking, and then from an inorganic perspective, we are looking for 1.5 to 2.5 of a revenue capital contribution throughout that period. Okay, if I then further zoom in, the diagnostic organic revenue expectation, the two and a half, you know, to, um, to, um, Four and a half. I would say that you look at the historical trend. For example, last year, diagnostics organic revenue grew 4.1%, and volume was 2.2, price mix was 1.9, right? You look at this year, and we just now talked about the data. I think for the first three quarters, we drew for organic revenue growth about 3.6% for diagnostics, and the volume growth is slightly outpacing the price So I would say when you continue to look beyond this year and think about the next few years, you know, we'll continue to expect, once again, the organic revenue growth to be in that range, and we'll continue to expect the volume growth to be a contributor in addition to price mix variability.

Kevin Caliendo, Analyst — UBS

Okay. Let's change topics to PAMA. We love PAMA. We love to talk about PAMA. Hopefully never again, but it's still an issue. You talked about $125 million as the potential impact. That's tied to traditional Medicare and Medicaid, and assumes the proposed fee schedule takes effect on 1-1-27. That's correct, I believe. Is there anything between now, we have the final rates have been published between now and then, is there anything that could swing that number one way or the other based on what you know now? And we can talk about results and everything, but let's just assume PAMA happens on 1-1-27. Is that 125? What are some of the variables that can maybe affect that one way or the other, and how to think about cost offsets to it as well?

Julia Wang, CFO

Yeah, yeah. We're clearly disappointed in the preliminary fee schedule released by CMS in September. The data essentially are really relying upon about 2% of the labs that were paid, and the Medicare part being 2024, with very limited data from physician office or hospital outreach labs. As a result, it is not representative of the commercial market, and therefore, it's not going to achieve the intended objective of PEM, right? With that being said, as you also teed up, that we did size the expected impact in 2007 to be about $125 million in remaining AOI before mitigation, and that's assuming it is implemented in the current design based on the current preliminary data. And that is really the impact tied to the traditional Medicare and Medicaid business in our portfolio. Now, in terms of how we expect that to evolve, there was a comment period in September, October. We did provide comment along with our trade association of ECLA, and now we are waiting for the final rate to be released. You know, of course, you know, how that final reimbursement rate looks like relative to the preliminary rate will be a factor that helps us better understand the potential impact in 27. But then the other key consideration is that, as we shared on the Q3 earnings call, you know, obviously, if you try to work through time of a given year with that magnitude of impact, it is impactful. But to also put things in perspective, it is slightly less than 1% of our enterprise revenue because we do have the portfolio diversification, right, of this PLS business that will not be impacted by PAMA. So as it relates to the multiple levers that we could potentially tap into to help us manage through the impact, of course, it starts with the strength in the utilization environment in diagnostics, as well as our ability to continue to drive above market growth in diagnostics. Continuing the momentum in BLS business, as we already talked a bit so far in this conversation. And then the M&A pipeline continues to be robust. We announced a few deals subsequent to Q3 closing, and we continue to progress in that regard. Last but not least, at the recent Investor Day, we shared that we are stepping up our efforts on driving more annual savings through our Launchpad initiatives, which is just really an enterprise operating efficiency initiative, right? Historically, that annual target from a savings perspective was about $100 to $125 million, and our expectations starting from $27 moving forward is really an increase to $125 to $150 million. And advanced technological improvements, including AI and robotics and everything in between, will be a key level behind that expected improvement. So, you know, we look forward to bring all of this together as we communicate the guidance for 2027 in just a short few months.

Kevin Caliendo, Analyst — UBS

There was a comment about some spillover into the rest of the business if PAMA were to take effect. Is that in your commercial book? There was some confusion in the marketplace around how a PAMA, I think we all understand there's Medicaid rates that are directly tied to the Medicare cliff rates. There was some consternation that commercial rates would be affected by this, but the belief was that a vast majority of your contracts... Would have had some protection against that. It had been rewritten over the last five years with PAMA's been written. Is that fair? And when you talk about some spillover, were you referring to Medicaid, or were you talking about commercial as well?

Julia Wang, CFO

Yeah, yeah. So as you were saying, right, so essentially, since PAMA was first implemented quite some time ago, we've been working very hard on really decoupling our commercial contracts with respect to their tie to the same as fee schedule. And at this point, the majority of our commercial contracts really is not tied to that phase schedule. There are still certain third-party contracts that have a knock-on effect if this were to be implemented. And we believe that the impact is manageable. We'll just manage that as part of the person takes on managing a very complex book of business. And the other consideration I wanted to be very, very clear is that, you know, PAMA is very disappointing. You know, the risk with it is really threatening the industry's sustainability, particularly the, you know, smaller players that doesn't have the scale, the financial strength and diversity to manage through or overcome it. And it's also not conducive for the patient access. But from a LabCorp perspective, you know, if it were to happen, we'll work through that. But it does not change fundamentally the long-term earnings power of our company, right? Because that margin trajectory has been established. It's going to be there, and we'll continue to work hard at maintaining and improving that.

Kevin Caliendo, Analyst — UBS

You were quite clear around a lot of the LRP. If Pam were to come back, there would be a lower end of the range. Can you still grill margins in the first year of PAMA from an enterprise basis? You're nodding your head.

Julia Wang, CFO

No, I'm nodding the head to your question, to just be clear. I'm acknowledging that I get your question, to be just super clear. So to go back to your question, right, on a more serious note, as you were saying, right, on the investor day, we did lay out that from a margin expansion perspective for the next three years, We are expecting an improvement of anywhere between 75 basis points to 150 basis points by the end of 2029, right? So we reaffirmed that guidance on the Q3 call. So I would say even with the latest development with PAMA, our view has not changed, broadly speaking. Now, if you take a particular year, say 2027, if PAMA does get implemented in the current design, You know, everything else being equal clearly, it would make it more challenging, right, to drive pure margin at the bottom line. But with that being said, just now I laid out a few factors that are just really multiple levers that we can tap into. And I would also say that the key takeaway here is it's not like we just have one lever that we have to solely rely upon as we look at the multiple levers to pull to manage a very complex business, right? Right now, I can reassure you that my entire finance team, along with the enterprise, are deeply engaged in really the annual operating plan process in really figuring out for next year, you know, what's the base case, what's the, you know, key assumptions that are going to move for us within the range that is either direction of the base case and how do we leverage all the leadership proposals to be able to have a plan for 2027 that is going to make sense. But also, it's going to be conducive for us to be on track to deliver against the three-year outlook that we just made out in September.

Kevin Caliendo, Analyst — UBS

Results Act, what do you think the chances are that this gets done? Is it 50-50 still? I know your analyst models are about 50-50, whether PAMA comes back next year. What do you think, honestly, is going to happen here? I know there's the ACLA view of it, but inside, when you're thinking about it, how do you think this is going to play out?

Julia Wang, CFO

I need to be very careful about nodding from this point forward. I just don't want that to be mistakenly interpreted as saying yes, but I'm saying yes to the question. So in all seriousness, yes.

Kevin Caliendo, Analyst — UBS

Is the results act going to be passed?

Julia Wang, CFO

So once again, we believe that is the right long-term solution for the industry. And in terms of the process, right, at this point, we're really waiting for the CBO scoring to be coming back. You know, clearly the outcome of that scoring will be influentially impactful as it relates to what could potentially be coming after that, right? If the scorer is suggesting that it's going to have a cost element that is more manageable than otherwise, then the pathway going from there could be more conducive than otherwise, right? And the opposite is also true, right? So I think at this moment, it's really stay tight and put in anticipating that result to come back. But in the meantime, I also would say, if PAMA gets implemented in the current design, we will continue to work with our trade association to push for legislation reform, because that's the right thing to do for healthcare system overrun for the patients, right? So that's the most important thing. And then lastly, of course, we are just prepared. As a business, we are prepared one way or another. And we feel that no matter how we land with PAMA, we are well positioned to measure that. And it's flu PEMA and then grow out of it and being stronger going forward.

Kevin Caliendo, Analyst — UBS

We only have a couple minutes left, and I still have about 10 questions, so this is going to be tough. But let's talk about some of the M&A deals. You just announced three deals. Really impressive. We've been waiting a while for deals, and these are good ones. Bioreference, Myriads, Prenatal Business, and Millennium. On the call. It wasn't clear to me whether you blessed. There was a question on the call about the potential accretion from bioreference and the margins of it, that the operating margin of the businesses in the low 20s, 22, 23 percent, to reach that 15 percent accretion. Is that math correct? Does that make sense?

Julia Wang, CFO

Yeah, so we are excited about the progress we have made as released to M&A, and you might recall in our past conversations, and Adam and I would have said that, yeah, the pipeline looks very healthy and robust, and you would be like, okay, so I'm going to announce. So, you know, we decided, you know, we take a moment and, but in all seriousness, you can imagine, right? Externally speaking, it appeared we announced those three deals within a week following the Q3 closing, but of course the work has been ongoing for quite some time and just coincidentally, you know, crossed the finish line from an announcement perspective at the same time. Now, if I start with the bio-reference deal, as you were saying, so the expectation is really a cash purchase of about $722 million with some earn-out structures associated with a 4K score test based on the revenue generation. And then the expectations to, once we are able to close the current anticipated close timing is about next year, but of course all the deals are subject to regulatory approval and the customary closing conditions, right? So from a financial standpoint, once we close the expectations to generate about $215 million in revenue in year one, and the margin, operating margin, is actually slightly higher than the segment margin for our diagnostic business. And once you take into account all the costs, including interest, it would really give you a just EPS contribution of $0.15 in year one. So when you look at this, it's a very holistic pro-former expectation, right? The other thing I would say is that businesses you know very, very well, we have partnered with BioReference for two deals previously already, right? There was a transaction in 24, a transaction in 25. So we definitely believe that we have a good understanding about their system, their way of working, their cost structure. So we look forward to being able to close the deal at the right time and then being able to really drive a lot more growth in the geographies that they are really strong at. And we're also very excited about potential to look at that footprint, particularly from a patient service center standpoint and our footprint and leverage those footprint from a very strong optimization perspective to take costs out of the system, being able to drive value that could drop to the bottom line.

Kevin Caliendo, Analyst — UBS

The M&A guidance for revenue, one and a half to two and a half percent. I'm guessing for 26, you're not going to necessarily have that much contribution, just given the timing of the deals. The three deals you announced already, does that get you to what would normally be the 1.5% to 2.5% growth for, say, 27, given that these are going to close? You can almost get a full-year contribution from three deals.

Julia Wang, CFO

So, as you were saying, the contribution from M&A, from a revenue category standpoint, is 1.5% to 2.5%. Last three years, we are on track about 2.4%, so the high end of that range. And then, you know, for 27, of course, we'll give more guidance as we lay that out in February of 27. But the short of long as part of that is also going to be dependent upon the timing of the closure, right, of the deals that we just announced. But with that being said, we are encouraged by the progress we've made as well as the pipeline that continues to be very healthy.

Kevin Caliendo, Analyst — UBS

Which Adam has said remains strong.

Julia Wang, CFO

Remains strong. So stay tuned.

Kevin Caliendo, Analyst — UBS

And hospital deals, maybe. Listen, thank you so much, Julia. We're out of time. Thank you so much. Thank you.